Clinical trialNCT03919162TerminatedPhase 2Interventional

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

SponsorVivoryon Therapeutics N.V.Enrollment112Alzheimer Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B. In Phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for Phase 2B is reached, then Phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Howard Feldman
Alzheimer's Disease Cooperative Study (ADCS)
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Barrow Neurological Institute
Phoenix, Arizona, United States
Banner Sun Health Research Institute
Sun City, Arizona, United States
the Neuron Clinic
Chula Vista, California, United States
University of California
Irvine, California, United States
Ucsd Alzheimer'S Disease Research Center
La Jolla, California, United States
Cedars-Sinai Center
Los Angeles, California, United States
Pcnd Neurology
Poway, California, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Usf Health Byrd Alzheimer'S Center and Research Institute
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
the University of Iowa Carver College of Medicine
Iowa City, Iowa, United States
the University of Kentucky Sanders-Brown Center on Aging
Lexington, Kentucky, United States
Northern Light Acadia Hospital
Bangor, Maine, United States
Nyu Langone Health Tisch Hospital
New York, New York, United States
Suny Upstate Medical University
Syracuse, New York, United States
Ohio State University
Columbus, Ohio, United States
Ohsu Neurology Clinic
Portland, Oregon, United States
Abington Neurological Associates
Abington, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Lowcountry Center for Veterans Research (lcvr)
Charleston, South Carolina, United States
Ut Health San Antonio
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PQ912

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Nov 2021
Primary completion: 12 Jul 2024
Completion: 12 Aug 2024
Last update posted: 12 Dec 2025
Registered enrollment: 112
Registry id: NCT03919162

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.